SOURCE: Kalorama Information

Kalorama Information

April 09, 2012 11:31 ET

Kalorama Information: Tests That Personalize Results Show Sales Growth of up to 38%

NEW YORK, NY--(Marketwire - Apr 9, 2012) - Diagnostic tests that can direct a therapy to a specific patient to boost outcomes and lower cost are experiencing faster sales growth, according to a recent report from Kalorama Information. The healthcare market research publisher tracks sales of this category of personalized medicine tests, reporting growth falling anywhere between 7% and 38% per year, compared with the more modest two to six percent growth in IVD generally.

"Tests that can green light a therapeutic option have so far beat the traditional IVD tests, which offer broad disease indicators," said Bruce Carlson, publisher of Kalorama Information. "We think this is the dynamic area of the IVD market and this is why scores of companies are heavily involved in this sector."

Tests, including Fluorescent In Situ Hybridization (FISH) for cancer screening, CYP450 tests for psychiatric therapy, individual microbiologic assessments to treat infectious disease and tissue transplant typing, rose to $28.1 billion in 2011, according to the report. Kalorama's market estimate covers tests that can also provide therapy decision-making information that is tailored to the individual, which falls into four categories: Tests that identify a population in which the therapeutic product will achieve greater (or little) effectiveness, tests that identify a patient population that should not receive a particular therapeutic product, tests that identify the characteristics of a disease, and tests that are the basis for selecting a safe and efficacious therapeutic dose.

The primary growth drivers in the market for personalized medicine tests are the continued discovery of protein and genetic markers with proven clinical utility, the increased adoption of these diagnostic tests as markers for personalized medicine and increased acceptance. There are challenges, such as reimbursement issues, lack of standardization across test platforms, limited quality control products and programs, as well as the inability to fully interpret test data.

Kalorama Information's study, "Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)" goes into detail about these challenges and their future impact on the market, lists specific personalized medicine tests that are poised to grow and profiles companies that are operating in these markets.

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact Information